Copeptin and Thirst: Possible Predictive Markers of Effectiveness of Bariatric Surgery?

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 28, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how certain markers in the body, specifically copeptin and thirst levels, might help predict how effective bariatric surgery will be for people struggling with obesity. Bariatric surgery is a procedure that helps patients lose weight, and understanding these markers could improve the overall success rates of the surgery.

To be eligible for the study, participants should be between 18 and 65 years old and have a body mass index (BMI) of 40 or higher, or a BMI of 35 or higher if they have related health issues. The trial is currently looking for volunteers, and those who join will be asked to provide their consent and follow specific health guidelines throughout the process. It's important to note that individuals with certain medical conditions, like serious mental health issues or those using specific medications, may not be able to participate. If you're interested, this study could offer valuable insights into how to better treat obesity and support patients undergoing bariatric surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • BMI ≥ 40 in the absence of comorbidities; BMI ≥ 35 associated with at least one comorbidity
• • Age ≥ 18 and less than or equal to 65 years
• • Written informed consent obtained
• Exclusion Criteria:
• Contraindications to bariatric surgery:
• • severe psychiatric illness in the decompensation phase;
• • drug or alcohol abuse;
• • patient unwilling to follow periodic checkups and a dietary regimen pregnancy or lactation.
• Factors that could alter ADH/copeptin:
• • Obesity induced by other endocrinopathies or medications;
• • Diabetes mellitus of any type;
• • Malignant neoplasms or ongoing acute disease;
• • Organ failure or chronic CNS and kidney disease;
• • Hydro-electrolyte alterations;
• • use of drugs that interfere with pituitary-adrenal axis, diuretics, anti-psychotics and psychopharmacological therapies, GLP1 receptor agonists, estro-progestin therapy.